P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV
Status:
Recruiting
Trial end date:
2021-08-23
Target enrollment:
Participant gender:
Summary
QPX7728 is an ultra-broad-spectrum beta-lactamase inhibitor, with activity against numerous
beta-lactamases, including class A extended spectrum beta-lactamases (ESBLs), class C
cephalosporinases, and extended spectrum class D oxacillinases (OXA) that can hydrolyze
cephalosporins and can be found in Enterobacteriaceae and Pseudomonas aeruginosa (P.
aeruginosa). QPX7728 is also a potent inhibitor of carbapenemases from all molecular classes,
such as class A Klebsiella pheumoniae carbapenemase (KPC), class B New-Dehli
Metalo-beta-lactamase (NDM) and Verona integron-encoded metallo-beta-lactamase (VIM), and
class D OXA-48 that are found in carbapenem resistant Enterobacteriaceae, and also class D
carbapenemases such as OXA-23 that are found in carbapenem resistant Acinetobacter baumannii.
Phase:
Phase 1
Details
Lead Sponsor:
Qpex Biopharma, Inc.
Collaborator:
Biomedical Advanced Research and Development Authority